← Back to Clinical Trials
Recruiting NCT01852448

Genetics of Insulin and Incretins in Cystic Fibrosis

Trial Parameters

Condition Cystic Fibrosis
Sponsor Children's Hospital of Philadelphia
Study Type OBSERVATIONAL
Phase N/A
Enrollment 550
Sex ALL
Min Age 2 Years
Max Age N/A
Start Date 2013-05
Completion 2026-07
Interventions
Blood or Saliva Sample Collection

Brief Summary

Cystic fibrosis related diabetes (CFRD) is associated with worse CF-relevant outcomes. The mechanisms underlying CFRD development are not fully understood, but recent evidence suggests Type 2 Diabetes Mellitus (T2DM) mechanisms may be involved and may involve incretins (gut secreted hormones that augment insulin secretion in response to a nutrient load). This study will examine the prevalence of Genome wide association study (GWAS)-implicated T2DM alleles (including TCF7L2) across the spectrum of glucose abnormalities in CF and will use this information to compare incretin and insulin secretion in non-diabetic children and adults with high risk and low risk alleles.

Eligibility Criteria

Inclusion Criteria 1. Subjects age \>2y 2. Diagnosis of Cystic Fibrosis 3. For subjects\< 18 years, parental/guardian permission (informed consent) and if appropriate, child assent Exclusion Criteria 1. Established diagnosis of non-CFRD (cystic fibrosis related diabetes) (e.g T1DM) .

Related Trials